top of page

Bonjour Europe

Find the latest drug approvals in Europe, HTA assessments, healthcare news

US–Swiss Tariff Cap Impact on Pharma: How the New US–Swiss Tariff Cap Shapes Pharma and Health Security

14 hours ago

EU clears Dupixent as first targeted CSU therapy in over a decade | iPharmaCenter

3 days ago

BMS' Breyanzi CAR-T Therapy Approved for Treating Mantle Cell Lymphoma | iPharmaCenter

Nov 25

European Drug Approvals | CHMP Positive Opinions | January 2025 | iPharmaCenter

Feb 3

Rybrevant plus Lazcluze approved in Europe for EGFR-NSCLC; showed improvement over Tagrisso | iPharmaCenter

Jan 2

Novartis’ Kisqali Gains European Commission Approval for Broader Use in Early Breast Cancer Patients at High Risk of Recurrence | iPharmaCenter

Dec 1, 2024

EMA Drug Approvals 2024 | CHMP Positive Opinion | October 2024 | iPharmaCenter

Oct 19, 2024

European Commission Greenlights Keytruda and Padcev Combo as First-Line Treatment for Advanced Urothelial Carcinoma | iPharmaCenter

Sep 3, 2024

European Commission Expands Approval for GSK's Arexvy, the First RSV Vaccine for Adults Aged 50-59 at Increased Risk | iPharmaCenter

Sep 1, 2024

Roche aims PNH market with SC PiaSky, aims to target AZ's Ultomiris market | iPharmaCenter

Aug 29, 2024

European Union Approves Ordspono for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma | iPharmaCenter

Aug 27, 2024

Leqembi (lecanemab) Approved in Great Britain for Early-Stage Alzheimer's Disease | iPharmaCenter

Leqembi (lecanemab) Approved in Great Britain for Early-Stage Alzheimer's Disease | iPharmaCenter

Leqembi (lecanemab) Approved in Great Britain for Early-Stage Alzheimer's Disease | iPharmaCenter

Aug 24, 2024

The European Commission Grants Approval for Tepkinly for a New Indication in Treating Relapsed/Refractory Follicular Lymphoma in Adults | iPharmaCenter

Aug 24, 2024

Dupixent (Dupilumab) Gains EU Approval as the First Targeted Therapy for COPD

Jul 4, 2024

Committee for Medicinal Products for Human Use | CHMP Positive Opinion | June | Europe Drug Approvals | 2024 | iPharmaCenter

Jul 2, 2024

European Commission Approves Roche's Alecensa as First Targeted Adjuvant Therapy for Early-Stage ALK-Positive Lung Cancer | 2024 | iPharmaCenter

Jun 10, 2024

Biogen Gains European Commission Approval for QALSODY (tofersen), a Novel Therapy for a Rare Genetic Form of ALS | EMA Drug Approvals | 2024 | iPharmaCenter

May 31, 2024

EMA Drug Approvals | Europe drug approvals | 2024 | iPharmaCenter

EMA Drug Approvals | Europe drug approvals | 2024 | iPharmaCenter

EMA Drug Approvals | Europe drug approvals | 2024 | iPharmaCenter

Apr 23, 2024

EMA Drug Approvals - CHMP Positive Opinions | March 2024 | iPharmaCenter

EMA Drug Approvals - CHMP Positive Opinions | March 2024 | iPharmaCenter

EMA Drug Approvals - CHMP Positive Opinions | March 2024 | iPharmaCenter

Mar 24, 2024

CHMP Positive Opinions | February | 2024 | iPharmaCenter

CHMP Positive Opinions | February | 2024 | iPharmaCenter

CHMP Positive Opinions | February | 2024 | iPharmaCenter

Feb 28, 2024

Medicines and Healthcare products Regulatory Agency | UK Drug approvals | News | iPharmaCenter

Medicines and Healthcare products Regulatory Agency | UK Drug approvals | News | iPharmaCenter

Medicines and Healthcare products Regulatory Agency | UK Drug approvals | News | iPharmaCenter

Nov 17, 2023

EMA Drug Approvals | CHMP Positive Opinions in October 2023 | Europe drug approvals | iPharmaCenter

EMA Drug Approvals | CHMP Positive Opinions in October 2023 | Europe drug approvals | iPharmaCenter

EMA Drug Approvals | CHMP Positive Opinions in October 2023 | Europe drug approvals | iPharmaCenter

Oct 17, 2023

Drug approvals in Europe| EMA drug approvals | 2023 |European Commission News| iPharmaCenter

Drug approvals in Europe| EMA drug approvals | 2023 |European Commission News| iPharmaCenter

Drug approvals in Europe| EMA drug approvals | 2023 |European Commission News| iPharmaCenter

Sep 27, 2023

CHMP Positive Opinions | EMA Drug Approvals | European Commission | 2023 | iPharmaCenter

CHMP Positive Opinions | EMA Drug Approvals | European Commission | 2023 | iPharmaCenter

CHMP Positive Opinions | EMA Drug Approvals | European Commission | 2023 | iPharmaCenter

Jul 26, 2023

Switzerland drug approvals | Swissmedic news | Blogs | 2023 | iPharmaCenter

Jul 10, 2023

Medicines and Healthcare products Regulatory Agency | News | 2023 Approvals | iPharmaCenter

Medicines and Healthcare products Regulatory Agency | News | 2023 Approvals | iPharmaCenter

Medicines and Healthcare products Regulatory Agency | News | 2023 Approvals | iPharmaCenter

May 16, 2023

2022 | CHMP Positive Opinions | EMA Drug Approvals | European Commission | Pharma | News

2022 | CHMP Positive Opinions | EMA Drug Approvals | European Commission | Pharma | News

2022 | CHMP Positive Opinions | EMA Drug Approvals | European Commission | Pharma | News

Feb 28, 2023

Drug approvals in Europe| EMA drug approvals in 2022 |European Commission News| iPharmaCenter

Drug approvals in Europe| EMA drug approvals in 2022 |European Commission News| iPharmaCenter

Drug approvals in Europe| EMA drug approvals in 2022 |European Commission News| iPharmaCenter

Jan 26, 2023

France healthcare News | HAS Sante | COVID 19 | Drug approvals | iPharmaCenter

France healthcare News | HAS Sante | COVID 19 | Drug approvals | iPharmaCenter

France healthcare News | HAS Sante | COVID 19 | Drug approvals | iPharmaCenter

Jan 6, 2023

COVID19 drug updates | FDA EMA approved COVID19 drugs

COVID19 drug updates | FDA EMA approved COVID19 drugs

COVID19 drug updates | FDA EMA approved COVID19 drugs

Oct 9, 2022

Opdualag was approved for unresectable/metastatic melanoma | LAG-3 inhibitors | Mode of action

Sep 19, 2022

European Commission approved Scemblix for chronic myeloid leukemia | iPharmaCenter

European Commission approved Scemblix for chronic myeloid leukemia | iPharmaCenter

European Commission approved Scemblix for chronic myeloid leukemia | iPharmaCenter

Aug 29, 2022

Roche’s Polivy was approved as first-line therapy for patients with DLBCL.

Roche’s Polivy was approved as first-line therapy for patients with DLBCL.

Roche’s Polivy was approved as first-line therapy for patients with DLBCL.

May 25, 2022

Germany HTA News | IQWIG and G-BA assessment news | Germany Pharma News

Germany HTA News | IQWIG and G-BA assessment news | Germany Pharma News

Germany HTA News | IQWIG and G-BA assessment news | Germany Pharma News

Dec 9, 2021

European Commission approved Roche's and Celltrion's monoclonal antibodies for COVID19

European Commission approved Roche's and Celltrion's monoclonal antibodies for COVID19

European Commission approved Roche's and Celltrion's monoclonal antibodies for COVID19

Nov 21, 2021

European Commission approved Benlysta for active lupus nephritis

European Commission approved Benlysta for active lupus nephritis

European Commission approved Benlysta for active lupus nephritis

May 9, 2021

France COVID-19 Updates | COVID-19 News in Europe

France COVID-19 Updates | COVID-19 News in Europe

France COVID-19 Updates | COVID-19 News in Europe

May 4, 2021

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

Apr 23, 2021

England patients to benefit from Phesgo, 5-minute breast cancer treatment from Roche

England patients to benefit from Phesgo, 5-minute breast cancer treatment from Roche

England patients to benefit from Phesgo, 5-minute breast cancer treatment from Roche

Apr 7, 2021

CHMP Opinions | EMA drug approvals

CHMP Opinions | EMA drug approvals

CHMP Opinions | EMA drug approvals

Mar 29, 2021

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Jan 12, 2021

Biogen initiated Phase 4 trial to determine the efficacy of Spinraza in Zolgensma treated patients

Jan 12, 2021

Kite’s CAR-Tcell therapy received approval in Europe for relapsed or refractory mantle cell lymphoma

Dec 28, 2020

European Commission to purchase 200 million doses of Johnson and Johnson's COVID 19 vaccine

European Commission to purchase 200 million doses of Johnson and Johnson's COVID 19 vaccine

European Commission to purchase 200 million doses of Johnson and Johnson's COVID 19 vaccine

Oct 9, 2020

HAS says Gilead's Veklury 'does not improve benefit' for COVID19 patients; EMA to review safety

HAS says Gilead's Veklury 'does not improve benefit' for COVID19 patients; EMA to review safety

HAS says Gilead's Veklury 'does not improve benefit' for COVID19 patients; EMA to review safety

Oct 3, 2020

ESMO 2020

ESMO 2020

ESMO 2020

Sep 19, 2020

Oxford vaccine trials were paused because of safety concerns; AZ said it’s ‘routine’

Oxford vaccine trials were paused because of safety concerns; AZ said it’s ‘routine’

Oxford vaccine trials were paused because of safety concerns; AZ said it’s ‘routine’

Sep 9, 2020

European Commission approved GSK’s Blenrep for relapsed and refractory multiple myeloma

European Commission approved GSK’s Blenrep for relapsed and refractory multiple myeloma

European Commission approved GSK’s Blenrep for relapsed and refractory multiple myeloma

Aug 27, 2020

JULY 2020 CHMP POSITIVE OPINION

Jul 26, 2020

European Commission approved Lynparza for metastatic pancreatic cancer

Jul 9, 2020

bottom of page